Galapagos Hit By Atopic Dermatitis Drug Fail
End For IL-7C Inhibitor Partnered With MorphoSys And Novartis
Executive Summary
The fundamentals for Galapagos are sound despite the failure of MOR106 for atopic dermatitis and two trials of filgotinib missing their primary endpoints for Sjögren’s syndrome and lupus.